Preface Section I: Anatomy and Physiology 1. Anatomy and Physiology of the Cochlea Karen S. Pawlowski, PhD 2. Anatomy and Physiology of the Vestibular System John A. Rutka, MD, FRCSC Section II: Systemic Toxicity 3. Salicylates, Nonsteroidal Anti-inflammatory Drugs, Quinine, and Heavy Metals Narayanan Prepageran, MD, FRCS, John A. Rutka, MD, FRCSC 4. Loop Diuretics Narayanan Prepageran, MD, FRCS, Andrew R.Scott, BM, BS, MPhil, FRCS (ORL-HNS), John A. Rutka, MD, FRCSC 5. Cinical Uses of Cisplatin Jeremy Sturgeon, MD, FRCPC 6. Platinum Compounds Michael Anne Gratton, PhD 7. Iron Chelating and Other Chemotherapeutic Agents: The Vinca Alkaloids Andrew R.Scott, BM, BS, MPhil, FRCS(ORL-HNS), Narayanan Prepageran, MD, FRCS, John A. Rutka, MD, FRCSC 8. Clinical Aminoglycoside Ototoxicity Coleman Rotstein, MD, FRCPC, Lionel A. Mandell, MD, FRCPC, FRCP (Lond) 9. Mechanisms for Aminoglycoside Toxicity: Basic Science Research Jochen Schacht, PhD 10. Macrolides Andrew R. Scott, BM, BS, MPhil, FRCS(ORL-HNS), John A. Rutka, MD, FRCSC Section III: Topical Toxicity 11. Middle Ear Effects of Ototopical Agents Charles G. Wright, PhD, Peter S. Roland, MD 12. Topical Aminoglycoside Cochlear Toxicity Peter S. Roland, MD, Charles G. Wright, PhD 13. Topical Aminoglycoside Vestibular Toxicity Narayanan Prepageran, MD, FRCS, Vitaly E. Kisilevsky, MD, John A. Rutka, MD, FRCSC 14. Chloramphenical, Colymyxin, and Polymyxin Leonard P. Rybak, MD, PhD, Srinivasan Krishna, MD, MPH 15. Topical Antifungals Lawrence W. C. Tom, MD, Lisa M. Elden, MS, MD, Roger R. Marsh, PhD 16. Surgical Disinfectants and Antiseptics Andrew R. Scott, BM, BS, MPhil, FRCS(ORL-HNS), Narayanan Prepageran, MD, FRCS, John A. Rutka, MD, FRCSC Section IV: Interventions 17. Genetic Factors in Aminoglycoside Ototoxicity Nathan Fischel-Ghodsian, MD 18. Audiologic Monitoring for Ototoxicity Kathleen C. M. Campbell, PhD 19. Monitoring Vestibular Ototoxicity Vitaly E. Kisilevsky, MD, David Tomlinson, PhD, Paul Ranalli, MD, FRCPC, Narayanan Prepageran, MD, FRCS 20. Treatment, Prevention, and Neural Regeneration Thomas R. Van De Water, MD, and Leonard P Rybak, MD, PhD Section V: Therapeutic Uses of Ototoxic Effects 21. Systemic Treatment of Bilateral Meniere's Disease Sumit K. Agrawal, MD, and Lorne S. Parnes, MD, FRCSC 22. Intratympanic Gentamicin in the Treatment of Meniere's Disease Brian W. Blakley, MD, PhD, FRCSC Section VI: Medicolegal Concerns 23. Medicolegal Concerns Peter E. Rhatican, JD, Sloan H. Mandell, LLB, and John A. Rutka, MD, FRCSC
 |
Ask a Question About this Product More... |
|
